Further positive data announced from SCOPE trial of SCIB1 with double CPIs for Advanced Melanoma November 19, 2024
Ph 1 and iMMagine-1 studies of anito-cel in R/R multiple myeloma patients continue to demonstrate durability and a manageable safety profile November 13, 2024
FAILED TRIAL: Ph 2/3 Study of Uproleselan Did Not Meet Primary Endpoint of EFS improvement in elderly 1L AML patients November 5, 2024
Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma Presented November 5, 2024
Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer Released November 5, 2024
Highly Significant Results In Ph 3 Study Of Ameluz®-Photodynamic Therapy (PDT) in Superficial Basal Cell Carcinoma (sBCC) Announced November 5, 2024
Positive Interim Ph 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer Announced October 29, 2024
Interim Clinical Proof-of-Concept Data for TYRA-300 in Ph 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) reported October 29, 2024
Updated Safety & Efficacy Data for Ph 1/2 Study of ONCT-534 for Treatment of R/R metastatic CRPC Announced October 29, 2024
ZL-1310 Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage SCLC October 29, 2024
Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma Presented October 29, 2024
Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma Presented October 29, 2024
Additional data from Ph 1 open-label, dose-escalation trial of PRT3789 in breast cancer patients with a SMARCA4 mutation announced October 29, 2024
IGCS 2024: Positive Updated RAMP 201 Data for Avutometinib & Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer Presented October 22, 2024
Positive and Statistically Significant OS and PFS Results for Zepzelca® (lurbinectedin) & Atezolizumab Combo in 1L Maintenance Therapy for ES-SCLC October 22, 2024
Positive Results from the Ongoing Clinical Trial of BTK Degrader NX-5948 in Patients with R/R Waldenstrom’s Macroglobulinemia Presented October 22, 2024
TAGRISSO + ORPATHYS demonstrated high, clinically meaningful response rate in NSCLC patients with MET overexpression and/or amplification in SAVANNAH Ph2 trial October 22, 2024
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with NMIBC in Ongoing Ph 1 Trial October 22, 2024
FAILED TRIAL: Ph 2 study of TG4001 + avelumab vs avelumab in patients with R/M HPV16-positive cervical and anogenital tumors did not meet the primary objective of PFS improvement October 15, 2024
KEYTRUDA Met Primary Endpoint of EFS as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced SCCHN October 15, 2024